Covid Hospitalizations in NYC Saw Biggest Racial Gap During Omicron
(Bloomberg) -- Black New Yorkers were hospitalized at two times the rate of White New Yorkers during the winter omicron surge. It's the widest disparity in hospitalizations seen in two years of the pandemic, according to the New York City Health Department.
“This is a significant inequity — and a particularly alarming one — so far into the pandemic,” said Michelle Morse, NYC Health's chief medical officer. And it came during a time when the dominant variant had a lower risk of hospitalization than its predecessor, delta.
Despite the city's relative success in closing race-based vaccination gaps, long-standing inequities in the U.S. health care system have proven difficult to overcome. A new report from the department highlights how a swath of social and economic factors contribute to disparate Covid-19 outcomes based on race.
Lagging booster rates among Black and Latino New Yorkers offer a glimpse into what's driving the higher hospitalization rates. Just over 20% of Black people, and around the same percentage of Latinos, received booster doses — well below the citywide average of 35%.
But Morse says to only look at booster rates, and even vaccinations, presents an “overly simplistic” explanation for why Black New Yorkers were so hard-hit by omicron.
“The other thing we know is at play here is how structural racism shapes social welfare, social wellbeing and health care access,” Morse said. “The cascade of factors we describe that lead to higher hospitalizations among Black people with omicron – structural racism shapes just about all of them.”
Black people had a higher burden of chronic disease well before the pandemic as access to quality health care has long missed marginalized communities. Co-morbidities, such as diabetes, that more commonly affect Black adults also increase the likelihood of getting very sick from Covid, according to the U.S. Centers for Disease Control and Prevention.
NYC Health observed a delay in the time between infection and diagnosis for Black residents. While most New Yorkers were diagnosed at least four days after the onset of symptoms, it took a day or more longer for Black New Yorkers. This delays Black people from getting treatment, such as monoclonal antibodies, Morse said, that can help prevent severe disease. The CDC reported that Black people have been 22% less likely to get monoclonal antibody treatment than White people since the therapy became available.
The report found that the delay between symptoms and diagnosis is largely because marginalized communities are likely to have fewer Covid-19 testing centers and tend to work in jobs where conditions make it difficult to get time off for testing. Plus, during the omicron surge, free testing centers were crushed by long lines, leading people to seek out alternative test options and sending Covid test prices soaring. For those who couldn't afford to buy overpriced online tests, there were few available options.
The U.S. has since emerged from the throes of omicron. The Biden administration has bolstered testing reserves, Covid cases continue to plummet and most mask requirements have been dropped.
Manhattan's Borough President Mark Levine said NYC Health's report comes at a critical time, serving as a reminder that the disparities exposed by the pandemic remain pertinent even in this next stage.
“It has huge implications for the decisions we're making right now on Covid policy, because the steps that we need to take to blunt a future wave clearly have racial equity implications,” Levine said. “We clearly see who is going to pay the price if there's another wave.”
©2022 Bloomberg L.P.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.